56.50
                                            Schlusskurs vom Vortag:
              $55.68
            Offen:
              $55.61
            24-Stunden-Volumen:
                859.18K
            Relative Volume:
              1.03
            Marktkapitalisierung:
                $3.17B
            Einnahmen:
              $665.13M
            Nettoeinkommen (Verlust:
              $64.50M
            KGV:
              49.38
            EPS:
                1.1442
            Netto-Cashflow:
                $185.87M
            1W Leistung:
              +8.61%
            1M Leistung:
              +18.70%
            6M Leistung:
                +73.90%
            1J Leistung:
              +62.03%
            Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
                  
                      Supernus Pharmaceuticals Inc
                    
                Sektor
                  Telefon
                  
                      301-838-2500
                    
                Adresse
                  
                      9715 KEY WEST AVENUE, ROCKVILLE, MD
                    
                Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                SUPN
                            
                             Supernus Pharmaceuticals Inc | 56.50 | 3.12B | 665.13M | 64.50M | 185.87M | 1.1442 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.10 | 63.79B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.23 | 43.49B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.18 | 40.30B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.03 | 23.21B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 453.53 | 20.59B | 3.08B | 1.24B | 1.07B | 25.61 | 
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight | 
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight | 
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral | 
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight | 
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral | 
| 2023-01-03 | Fortgesetzt | Jefferies | Buy | 
| 2021-12-01 | Fortgesetzt | Jefferies | Buy | 
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy | 
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight | 
| 2020-06-15 | Fortgesetzt | Jefferies | Hold | 
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold | 
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold | 
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold | 
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy | 
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy | 
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy | 
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy | 
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy | 
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy | 
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold | 
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral | 
| 2017-07-14 | Eingeleitet | Janney | Neutral | 
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight | 
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform | 
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral | 
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy | 
| 2015-11-05 | Bestätigt | Northland Capital | Outperform | 
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform | 
                    Alle ansehen
                     
                  
                Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Can Supernus Pharmaceuticals Inc. stock continue upward trendPortfolio Performance Report & Long Hold Capital Preservation Plans - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo
Supernus Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Update & Consistent Profit Alerts - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Why Supernus Pharmaceuticals Inc. stock remains undervaluedTrade Entry Summary & Safe Capital Allocation Plans - newser.com
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
Top chart patterns to watch in Supernus Pharmaceuticals Inc.Watch List & Verified Short-Term Plans - newser.com
What institutional flow reveals about Supernus Pharmaceuticals Inc.Treasury Yields & Community Verified Trade Alerts - newser.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in
Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com
Supernus a new buy at BofA on 'underappreciated' CNS assets - Seeking Alpha
Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance
Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo
BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener
B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq
Is Supernus Pharmaceuticals Inc. stock near bottom after decline2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementTrade Analysis Summary & Safe Entry Trade Reports - newser.com
It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance
Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - sharewise.com
Is Supernus Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Investment Summary & Smart Swing Trading Alerts - Fundação Cultural do Pará
Is Supernus Pharmaceuticals Inc. stock attractive after correctionEntry Point & Low Drawdown Trading Strategies - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com
How Supernus Pharmaceuticals Inc. stock reacts to Fed rate cutsTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App